Home › News › Industrial talks

Glenmark Pharma to study potential Covid-19 drug combination

Glenmark Pharma to study potential Covid-19 drug combination

Glenmark Pharmaceuticals Ltd said on Tuesday it would begin a clinical trial in India to test a combination of two antiviral drugs, favipiravir, and umifenovir, as a potential COVID-19 treatment.

Glenmark has secured Indian regulatory approval for the study, which will aim to enroll 158 hospitalized patients with moderate COVID-19, the company said.
Drugmakers across the world have been rushing to develop a treatment or vaccine for the novel coronavirus, which has infected 5.5 million people globally, killing more than 345,000, according to a Reuters tally. In India, now among the 10 most-affected nations, the death toll reached 4,167 on Tuesday.

Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while umifenovir is licensed as a treatment for some types of flu infections in Russia and China.

Glenmark Pharma to study potential Covid-19 drug combination

Darshana

  • Info 1
  • Info 2
  • Info 3
More news about: industrial talks | Published by Darshana | May - 26 - 2020 | 201

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology